---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-019645"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-07-15T23:59:59+00:00"
generated_at: "2026-05-18T06:32:42.485230+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC

## Summary
- No dose-limiting toxicities or unexpected adverse events in first 10 patients.
- No Grade 3 or 4 toxicities observed; side effects manageable with standard care.
- Phase 2 trial to enroll 100 patients; interim efficacy data expected September 2025.
- Company plans to discuss potential pivotal Phase 3 study design with regulators.

## SEC filing metadata
- accession: 0001641172-25-019645
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000164117225019645/0001641172-25-019645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000164117225019645/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-019645
- JSON: https://secwatch.observer/filing/0001641172-25-019645.json
- Plain text: https://secwatch.observer/filing/0001641172-25-019645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.